The Cryopyrin-associated Periodic Syndromes market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cryopyrin-associated Periodic Syndromes pipeline products will significantly revolutionize the Cryopyrin-associated Periodic Syndromes market dynamics.  

DelveInsight’s “Cryopyrin-associated Periodic Syndromes Market Insights, Epidemiology, and Market Forecast-2034″ reportoffers an in-depth understanding of the Cryopyrin-associated Periodic Syndromes, historical and forecasted epidemiology as well as the Cryopyrin-associated Periodic Syndromes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Cryopyrin-associated Periodic Syndromes market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Cryopyrin-associated Periodic Syndromes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cryopyrin-associated Periodic Syndromes Market Insights

Some of the key facts of the Cryopyrin-associated Periodic Syndromes Market Report: 

• The Cryopyrin-associated Periodic Syndromes market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In March 2024, Ventyx Biosciences, Inc. successfully completed a Phase 2 trial of VTX2735 in patients with cryopyrin-associated periodic syndromes (CAPS), a group of rare autoinflammatory disorders caused by gain-of-function mutations in the NLRP3 gene. The trial included 7 patients with familial cold autoinflammatory syndrome (FCAS), the most common CAPS subset. Treatment with VTX2735 showed significant clinical improvements, including an 85% average reduction in the Key Symptom Score during Treatment Period 1. Inflammatory biomarker levels also decreased, aligning with improved disease activity. VTX2735 was well-tolerated, with all drug-related adverse events reported as mild. These results provide strong clinical proof of concept for VTX2735 as a peripheral NLRP3 inhibitor.

• In 2023, the market size in the United States was estimated at approximately USD 40 million. The anticipated introduction of new therapies is expected to drive growth in the overall CAPS market size throughout the study period (2020–2034).

• Canakinumab was the top revenue-generating approved therapy in the United States in 2023, with earnings of approximately USD 25 million.

• In 2023, the United States had approximately 700 total prevalent cases, a number expected to rise during the forecast period.

• Approximately 500 cases of CAPS were diagnosed in the United States in 2023

• In 2023, the total CAPS cases in the United States included approximately 10 cases in individuals under 4 years old, around 150 cases in those aged 4–17 years, and about 300 cases in individuals aged 18 and older.

• Key Cryopyrin-associated Periodic Syndromes Companies: Amgen, Biovitrum, Novartis, Ventyx Biosciences, and others

• Key Cryopyrin-associated Periodic Syndromes Therapies: KINERET (Anakinra), ILARIS (Canakinumab), VTX2735, and others

Cryopyrin-associated Periodic Syndromes Overview

Cryopyrin-associated Periodic Syndromes Syndromes (CAPS) is a rare group of auto-inflammatory as well as known autosomal dominant disorder that is believed to be caused due to a mutation on the exon 3 of theNLRP3gene which codes for Cryopyrin protein.

Get a Free sample for the Cryopyrin-associated Periodic Syndromes Market Report – 

https://www.delveinsight.com/report-store/cryopyrin-associated-periodic-syndromes-caps-market

Cryopyrin-associated Periodic Syndromes Market  

The dynamics of the Cryopyrin-associated Periodic Syndromes market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034. 

Cryopyrin-associated Periodic Syndromes Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Cryopyrin-associated Periodic Syndromes epidemiology trends @ Cryopyrin-associated Periodic Syndromes Epidemiological Insights

Cryopyrin-associated Periodic Syndromes Epidemiology Segmentation:

The Cryopyrin-associated Periodic Syndromes market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Cryopyrin-associated Periodic Syndromes

• Prevalent Cases of Cryopyrin-associated Periodic Syndromes by severity

• Gender-specific Prevalence of Cryopyrin-associated Periodic Syndromes

• Diagnosed Cases of Episodic and Chronic Cryopyrin-associated Periodic Syndromes

Cryopyrin-associated Periodic Syndromes Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cryopyrin-associated Periodic Syndromes market or expected to get launched during the study period. The analysis covers Cryopyrin-associated Periodic Syndromes market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cryopyrin-associated Periodic Syndromes Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cryopyrin-associated Periodic Syndromes Therapies and Key Companies

• KINERET (Anakinra): Amgen/Biovitrum

• ILARIS (Canakinumab): Novartis

• VTX2735: Ventyx Biosciences

• DFV890: Novartis

To know more about Cryopyrin-associated Periodic Syndromes treatment, visit @ Cryopyrin-associated Periodic Syndromes Medications

Cryopyrin-associated Periodic Syndromes Market Drivers

• Improvement in the treatment strategies

• Advances in Research and Development

• Less competitive scenario

Cryopyrin-associated Periodic Syndromes Market Barriers

• Lack of awareness in the care providers

• High cost of research and low return on investment

• Limited patient population in clinical trials

Scope of the Cryopyrin-associated Periodic Syndromes Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Cryopyrin-associated Periodic Syndromes Companies: Amgen, Biovitrum, Novartis, Ventyx Biosciences, and others

• Key Cryopyrin-associated Periodic Syndromes Therapies: KINERET (Anakinra), ILARIS (Canakinumab), VTX2735, and others

• Cryopyrin-associated Periodic Syndromes Therapeutic Assessment: Cryopyrin-associated Periodic Syndromes current marketed and Cryopyrin-associated Periodic Syndromes emerging therapies

• Cryopyrin-associated Periodic Syndromes Market Dynamics: Cryopyrin-associated Periodic Syndromes market drivers and Cryopyrin-associated Periodic Syndromes market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Cryopyrin-associated Periodic Syndromes Unmet Needs, KOL’s views, Analyst’s views, Cryopyrin-associated Periodic Syndromes Market Access and Reimbursement 

Discover more about therapies set to grab major Cryopyrin-associated Periodic Syndromes market share @ Cryopyrin-associated Periodic Syndromes market forecast 

Table of Contents 

1. Cryopyrin-associated Periodic Syndromes Market Report Introduction

2. Executive Summary for Cryopyrin-associated Periodic Syndromes

3. SWOT analysis of Cryopyrin-associated Periodic Syndromes

4. Cryopyrin-associated Periodic Syndromes Patient Share (%) Overview at a Glance

5. Cryopyrin-associated Periodic Syndromes Market Overview at a Glance

6. Cryopyrin-associated Periodic Syndromes Disease Background and Overview

7. Cryopyrin-associated Periodic Syndromes Epidemiology and Patient Population

8. Country-Specific Patient Population of Cryopyrin-associated Periodic Syndromes 

9. Cryopyrin-associated Periodic Syndromes Current Treatment and Medical Practices

10. Cryopyrin-associated Periodic Syndromes Unmet Needs

11. Cryopyrin-associated Periodic Syndromes Emerging Therapies

12. Cryopyrin-associated Periodic Syndromes Market Outlook

13. Country-Wise Cryopyrin-associated Periodic Syndromes Market Analysis (2020–2034)

14. Cryopyrin-associated Periodic Syndromes Market Access and Reimbursement of Therapies

15. Cryopyrin-associated Periodic Syndromes Market Drivers

16. Cryopyrin-associated Periodic Syndromes Market Barriers

17.  Cryopyrin-associated Periodic Syndromes Appendix

18. Cryopyrin-associated Periodic Syndromes Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsights

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/